Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metabolism-based anticancer drug design.

C H Kwon1

  • 1Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. Johns University, Jamaica, New York 11439, USA. kwonc@stjohns.edu

Archives of Pharmacal Research
|January 1, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load.

Journal of viral hepatitis·2014
Same author

Serpin peptidase inhibitor clade A member 1 is a biomarker of poor prognosis in gastric cancer.

British journal of cancer·2014
Same author

PATHOME: an algorithm for accurately detecting differentially expressed subpathways.

Oncogene·2014
Same author

Clinical significance of proteinuria at posttransplant year 1 in kidney transplantation.

Transplantation proceedings·2012
Same author

Monitoring of cytomegalovirus-specific CD8+ T-cell response with major histocompatibility complex pentamers in kidney transplant recipients.

Transplantation proceedings·2011
Same author

Alemtuzumab induction in deceased donor kidney transplantation.

Transplantation proceedings·2011
Same journal

Tumor organoid platform design for drug response modeling: culture architecture, microenvironmental complexity, and AI-assisted readouts.

Archives of pharmacal research·2026
Same journal

Acetylation-dependent regulation of FOX-Ku interaction by GCN5-SIRT1 axis controls non-homologous end-joining DNA repair.

Archives of pharmacal research·2026
Same journal

Exercise-induced myokines in metabolic regulation: mechanisms, mimetics, and translational potential.

Archives of pharmacal research·2026
Same journal

eHsp90α enhances breast cancer cell invasion by activating the LRP1-EGFR/AKT-twist/snail signaling axis in cancer-associated fibroblasts.

Archives of pharmacal research·2026
Same journal

Liver organoids for chemical risk assessment: biological fidelity, standardization, and context-of-use frameworks.

Archives of pharmacal research·2026
Same journal

M2 microglial exosomal miR-1949 ameliorates sepsis-associated encephalopathy through DKK1/Wnt/β-catenin-mediated microglial repolarization.

Archives of pharmacal research·2026
See all related articles

Researchers are developing novel anticancer prodrugs that exploit selective metabolic processes for activation, aiming to improve efficacy against resistant solid tumors and reduce side effects of conventional chemotherapy.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Drug Discovery

Background:

  • Conventional anticancer drugs often lack selectivity for cancer cells, leading to poor efficacy against solid tumors and significant side effects.
  • Mechanisms like drug resistance, increased glutathione transferases, and enhanced DNA repair reduce the effectiveness of existing chemotherapies.
  • Solid tumors frequently exhibit hypoxic environments, contributing to resistance against radiation and chemotherapy.

Purpose of the Study:

  • To review recent advancements in anticancer prodrug design.
  • To highlight strategies that leverage selective metabolic activation for improved therapeutic outcomes.
  • To focus on prodrugs targeting the unique characteristics of solid tumors, such as hypoxia.

Main Methods:

  • Review of recent scientific literature on anticancer prodrug development.

Related Experiment Videos

  • Analysis of prodrug activation mechanisms, particularly those exploiting selective metabolic pathways.
  • Emphasis on prodrugs designed for hypoxic tumor environments, including nitroheterocyclic agents.

    • Main Results:

    • Development of bioreversible prodrugs, such as those for cyclophosphamide (phosphoramide mustard), aims to enhance the therapeutic index.
    • Exploitation of nitroheterocyclics activated by nitroreductase enzyme systems shows promise for hypoxic solid tumors.
    • Selective metabolic activation offers a strategy to improve drug targeting and overcome resistance mechanisms.

    Conclusions:

    • Anticancer prodrug design focusing on selective metabolic activation is a promising approach to overcome limitations of conventional therapies.
    • Targeting hypoxic tumor microenvironments with specifically activated prodrugs can enhance anti-cancer efficacy.
    • Further research into prodrug strategies holds potential for developing more effective and selective cancer treatments.